Isabelle J Pouliquen
Overview
Explore the profile of Isabelle J Pouliquen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh D, Fuhr R, Bird N, Mole S, Hardes K, Man Y, et al.
Br J Clin Pharmacol
. 2021 Jul;
88(2):702-712.
PMID: 34292606
Aims: GSK3511294 is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb) engineered for extended half-life and improved IL-5 affinity versus other anti-IL-5 mAbs. This study examined its safety, tolerability, pharmacokinetics (PK)...
2.
Pouliquen I, Austin D, Steinfeld J, Yancey S
Clin Ther
. 2021 Jun;
43(7):1278-1280.
PMID: 34187697
No abstract available.
3.
Best N, Price R, Pouliquen I, Keene O
Pharm Stat
. 2021 Jan;
20(3):551-562.
PMID: 33475231
Assessment of efficacy in important subgroups - such as those defined by sex, age, race and region - in confirmatory trials is typically performed using separate analysis of the specific...
4.
Kang E, Narayana P, Pouliquen I, Lopez M, Ferreira-Cornwell M, Getsy J
Allergy
. 2019 Sep;
75(4):950-953.
PMID: 31515809
No abstract available.
5.
Shabbir S, Pouliquen I, Bentley J, Bradford E, Kaisermann M, Albayaty M
Clin Pharmacol Drug Dev
. 2019 Jul;
9(3):375-385.
PMID: 31317668
This study compared the pharmacokinetic (PK) profile of a new liquid formulation of mepolizumab with the established lyophilized formulation. In this open-label, parallel-group, single-dose study (NCT03014674; GSK ID: 204958), healthy...
6.
Pouliquen I, Kornmann O, Barton S, Price J, Ortega H
Int J Clin Pharmacol Ther
. 2015 Oct;
53(12):1015-27.
PMID: 26445140
Objective: Mepolizumab is a humanized IgG1 monoclonal antibody that blocks human IL-5 from binding to the IL-5 receptor, which is mainly expressed on eosinophils. Eosinophils are key cells in the...
7.
De Boever E, Ashman C, Cahn A, Locantore N, Overend P, Pouliquen I, et al.
J Allergy Clin Immunol
. 2014 Mar;
133(4):989-96.
PMID: 24582316
Background: Approximately 5% to 10% of asthmatic patients achieve incomplete symptom control on current therapies. The association of IL-13 with asthma pathology and reduced corticosteroid sensitivity suggests a potential benefit...
8.
Cahn A, Tal-Singer R, Pouliquen I, Mehta R, Preece A, Hardes K, et al.
Clin Drug Investig
. 2013 Jun;
33(7):477-88.
PMID: 23784369
Background: Chronic obstructive pulmonary disease (COPD) has a significant negative impact on quality of life and increases the risk of premature death. Umeclidinium is a long-acting muscarinic receptor antagonist in...
9.
Tal-Singer R, Cahn A, Mehta R, Preece A, Crater G, Kelleher D, et al.
Eur J Pharmacol
. 2013 Jan;
701(1-3):40-8.
PMID: 23276660
To characterise the safety, tolerability, pharmacodynamics (bronchodilatory effect) and pharmacokinetics of inhaled umeclidinium in patients with chronic obstructive pulmonary disease (COPD). The first investigation was a single dose, randomised, double-blind,...
10.
He M, Abraham T, Lindsay T, Schaefer H, Pouliquen I, Payne C, et al.
Drug Metab Dispos
. 2003 Feb;
31(3):334-42.
PMID: 12584161
The metabolism and pharmacokinetics of moxonidine, a potent central-acting antihypertensive agent, were studied in four healthy subjects after a single oral administration of approximately 1 mg (approximately 60 muCi) of...